Explore licensed vaccines, adverse event reporting data, and history for this disease.
- Phase 1
- Phase 2
- Phase 3
- Filed
- Approved
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Submission Filed Date: 2026-01Company-reported filing; confirm against FDA docket before treating as regulator-confirmed |
| EMA (Europe) | Submission Filed Date: 2026-01 |
| Health Canada | Submission Filed Date: 2026-01 |
| TGA (Australia) | Submission Filed Date: 2026-01 |
Progress and adoption outlook
Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Dates are the company's own estimates.
- Preclinical
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Submitted to a regulator
- Under regulatory review
- Approved / authorised
- Recommended for routine use
Current position: Submitted to a regulator
| Jurisdiction | Status in the record | Submission | Regulator decision | Earliest routine use |
|---|---|---|---|---|
| United StatesFDA (CBER) · ACIP (CDC) | regulatory submission filed (2026-01, company estimate) | 2026-012026-01 to 2026-01 | 2026-112026-11 to 2027-04 | 2027-022026-11 to 2027-12 |
| European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others) | regulatory submission filed (2026-01, company estimate) | 2026-012026-01 to 2026-01 | 2027-032026-10 to 2027-09 | 2027-092026-11 to 2029-03 |
| CanadaHealth Canada · NACI | regulatory submission filed (2026-01, company estimate) | 2026-012026-01 to 2026-01 | 2026-112026-11 to 2027-04 | 2027-032026-12 to 2028-04 |
| United KingdomMHRA · JCVI | no jurisdiction-specific filing known | The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used. | ||
| AustraliaTGA · ATAGI | regulatory submission filed (2026-01, company estimate) | TGA registration-timeframe pages timed out on 2026-10-24; no target is used. | ||
| JapanPMDA / MHLW · MHLW immunisation subcommittee | no jurisdiction-specific filing known | PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure. | ||
| WHO prequalificationWHO Prequalification · SAGE | no jurisdiction-specific filing known | WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used. | ||
Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.
Scientific Profile & Documentation
- Platform Architecture
- mRNA
- Lead Developer
- Moderna
- Next Expected Milestone
- Regulatory decision(s) pending across filed jurisdictions (company projection)
- Analyst & Development Notes
- Company-projected timelines frequently slip; treat next-milestone dates as company estimates.
- Primary Source Documentation
- Moderna Analyst Day pipeline update (press summary) →
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.
Milestone Overview
-
Stage VerificationRegulatory Submission Filed confirmed as of 2026-07-10.
-
Target MilestoneRegulatory decision(s) pending across filed jurisdictions (company projection)
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.